Otonomy begins mid-stage trial of OTO-313 in tinnitus

|About: Otonomy, Inc. (OTIC)|By:, SA News Editor

Otonomy (NASDAQ:OTIC) has initiated a Phase 1/2 clinical trial of OTO-313, a sustained-exposure formulation of the NMDA receptor antagonist gacyclidine, in patients with tinnitus.

The study will include an initial safety cohort followed by an exploratory efficacy study that will enroll  approx.50 patients with subjective tinnitus.

Results from the trial are expected in H1 2020.

Subscribe for full text news in your inbox